Can a growth factor protein heal stubborn leg ulcers?

NCT ID NCT00425178

NEW Completed Disease control Sponsor: Venturis Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This early-stage trial is testing whether a single topical application of FGF-1, a protein that helps cells grow, is safe for people with diabetic or venous stasis ulcers. The study enrolls a small group of adults with full-thickness leg ulcers that have lasted at least 8 weeks. Researchers will monitor safety, how the body processes the drug, and any signs of wound improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FGF-1 (human fibroblast growth factor-1), a protein applied topically to the wound
What this could lead to: If safe and effective, FGF-1 could become a new topical treatment to help heal chronic diabetic or venous ulcers.
What could go wrong: This is a very early, small pilot study focused on safety, not proof of healing. The treatment may not improve wounds or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC WOUNDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus ulcer disease Varicose Ulcer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC WOUNDS DIABETES VENOUS STASIS ULCERS

Contacts and locations

Locations

Warren General Hospital

Warren, Pennsylvania, 16365, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.